Can I Take Resveratrol with Vyvanse?

What Is Vyvanse and How Does It Work?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a Schedule II CNS stimulant approved by the FDA for ADHD in children aged 6 and older, adolescents, and adults, as well as for moderate-to-severe binge eating disorder in adults. [1] The drug is a prodrug. After oral ingestion, peptide hydrolase enzymes inside red blood cells cleave the lysine moiety to release active d-amphetamine.

The Prodrug Conversion Step

Because the conversion happens inside red blood cells rather than in the liver, lisdexamfetamine is considered less susceptible to first-pass hepatic metabolism than immediate-release amphetamine formulations. That step is enzymatic and relatively fixed in healthy adults, which is one reason Vyvanse carries a lower abuse potential than free amphetamine salts. [2]

How Amphetamine Is Cleared

Once d-amphetamine is circulating, the body clears it through several routes. Monoamine oxidase (MAO) converts a portion to inactive metabolites. CYP2D6 handles another fraction, producing 4-hydroxyamphetamine. CYP3A4 contributes to N-demethylation of amphetamine at higher substrate concentrations. Urinary excretion of unchanged amphetamine is pH-dependent: alkaline urine slows elimination and raises plasma levels, while acidic urine accelerates it. [3]

The FDA-approved prescribing information for Vyvanse lists CYP2D6 as the main hepatic enzyme involved in amphetamine metabolism and identifies MAO inhibitors as the most dangerous drug interaction class. [1]

What Is Resveratrol?

Resveratrol (3,5,4-trihydroxystilbene) is a stilbenoid polyphenol produced by plants under stress. Grapes, blueberries, peanuts, and the root of Polygonum cuspidatum (Japanese knotweed) are the most common dietary and supplement sources. Commercial products range from 50 mg to 1,000 mg per capsule, and some longevity-focused protocols use 500 mg to 2,000 mg daily.

Proposed Health Benefits

Resveratrol activates SIRT1 (a NAD-dependent deacetylase), inhibits NF-kB inflammatory signaling, and shows antioxidant activity in cell and animal models. [4] Human trial results have been inconsistent. A 2018 meta-analysis in the journal Nutrients (19 RCTs, N=1,202) found modest reductions in fasting glucose and insulin in people with metabolic syndrome but no significant change in body weight. [5]

Estrogenic Activity

Resveratrol binds estrogen receptors ERα and ERβ with low affinity. At pharmacological doses (above ~300 mg/day), it may exert weak estrogenic effects. [6] This is relevant for women on Vyvanse who are also managing hormonal conditions, though the clinical magnitude of this effect at typical supplement doses remains under study.

CYP Enzyme Inhibition

This is where the pharmacokinetic concern begins. In vitro and some human pharmacokinetic studies show resveratrol inhibits:

• CYP3A4 (competitive inhibition, IC50 approximately 11 µM in microsomal assays)
• CYP1A2 (moderate inhibition)
• CYP2D6 (weak inhibition at lower concentrations, moderate at doses above 1,000 mg) [7]

Because CYP2D6 and CYP3A4 both participate in amphetamine metabolism, the theoretical concern is that high-dose resveratrol could slow d-amphetamine clearance and push plasma amphetamine levels higher than intended.

Does Resveratrol Actually Interact With Vyvanse? The Evidence So Far

Direct human studies pairing lisdexamfetamine with resveratrol do not exist in the published literature as of mid-2025. The interaction assessment below is built from mechanistic pharmacokinetics and studies of resveratrol's effect on co-administered drugs metabolized by the same enzymes.

CYP3A4 Inhibition: What the Data Shows

A 2010 pharmacokinetic study by Chow et al. In Cancer Epidemiology, Biomarkers & Prevention (N=8 healthy volunteers) found that a single 1,000 mg dose of resveratrol inhibited CYP3A4 activity, measured by midazolam AUC, by roughly 30%. Repeat dosing at 1,000 mg/day for 4 days produced similar CYP3A4 inhibition. [8] Midazolam is a sensitive CYP3A4 substrate, so this is a meaningful signal.

A smaller fraction of amphetamine metabolism runs through CYP3A4 compared with CYP2D6, which partially limits the clinical impact. But in CYP2D6 poor metabolizers (approximately 6-10% of European-ancestry individuals) who already rely more heavily on CYP3A4 for amphetamine clearance, the effect of CYP3A4 inhibition by resveratrol could be more pronounced. [9]

CYP2D6: Resveratrol's Effect at Supplement Doses

At doses of 150-500 mg/day, resveratrol shows weak-to-negligible CYP2D6 inhibition in human pharmacokinetic studies. At doses of 1,000 mg/day and above, some studies detect a modest rise in the AUC of CYP2D6 probe substrates, though the magnitude is generally smaller than the effect on CYP3A4. [7] Because CYP2D6 is the primary hepatic route for amphetamine 4-hydroxylation, even weak inhibition at this enzyme could contribute to slightly elevated d-amphetamine exposure over time.

What This Means Clinically

If resveratrol slows amphetamine clearance, even modestly, a patient on a fixed Vyvanse dose might notice:

• Longer or more intense stimulant effects later in the day
• Worsened insomnia if the interaction delays the amphetamine half-life
• Elevated resting heart rate or blood pressure
• Increased anxiety or jitteriness

None of these are guaranteed. The magnitude of the interaction is likely dose-dependent on the resveratrol side, with supplement doses below 250 mg/day posing minimal pharmacokinetic risk based on available CYP inhibition data.

Pharmacodynamic Concerns: Cardiovascular and CNS Overlap

Beyond enzyme interactions, there are two pharmacodynamic dimensions worth considering.

Cardiovascular Effects

Vyvanse raises heart rate and blood pressure through its sympathomimetic mechanism. At therapeutic doses in ADHD trials, mean systolic BP increases of 1-4 mmHg and heart rate increases of 3-6 bpm were observed compared to placebo. [1] Resveratrol at lower doses (150 mg/day) generally shows mild vasodilatory and cardioprotective effects in human trials. [10] The directional effects are somewhat opposite, which may sound reassuring, but the interaction has not been studied in combination, and individual responses vary substantially.

CNS Stimulation and Serotonin Signaling

Resveratrol has demonstrated MAO-inhibiting activity in animal and in vitro models at high concentrations. [11] This is relevant because MAO inhibitors are contraindicated with Vyvanse due to the risk of hypertensive crisis. The concentrations at which resveratrol inhibits MAO in vitro are substantially higher than typical plasma levels from oral supplementation, so this is more a theoretical flag than a documented clinical risk at standard doses. Still, patients should not combine resveratrol with Vyvanse during or within 14 days of stopping a pharmaceutical MAO inhibitor.

Who Is at Greatest Risk?

Not every person on Vyvanse faces the same risk profile with resveratrol.

Higher-Risk Scenarios

• CYP2D6 poor metabolizers. Genetic testing (pharmacogenomics) can identify this group. These individuals already clear amphetamine more slowly than average and depend more on CYP3A4, meaning resveratrol's CYP3A4 inhibition may have a larger impact on their amphetamine levels.
• High resveratrol doses (above 500 mg/day). The CYP inhibition data becomes more clinically meaningful at these levels.
• Patients on higher Vyvanse doses (50-70 mg/day). At the higher end of the therapeutic range, even a modest increase in amphetamine AUC translates to a larger absolute change in plasma drug concentration.
• People with pre-existing cardiovascular conditions. Any additive or subtractive effect on heart rate or blood pressure warrants closer monitoring.

Lower-Risk Scenarios

• Dietary resveratrol from food (red wine, grapes). The amounts consumed from food are far below supplement doses.
• Resveratrol supplements at 50-150 mg/day, which fall below the thresholds for meaningful CYP inhibition seen in pharmacokinetic studies.
• Patients already stable on Vyvanse for several months who want to start a low-dose resveratrol product, with provider knowledge and baseline vital sign documentation.

Practical Guidance: How to Use Both If Your Provider Approves

The following tiered framework summarizes the decision logic a HealthRX clinical pharmacist uses when reviewing Vyvanse patients who want to add resveratrol. It is not a substitute for individualized clinical advice.

Tier 1: Clearance and Baseline (Before Starting)

1. Tell the prescribing clinician you are considering resveratrol. Bring the specific product, because dose matters.
2. Record a baseline resting heart rate and blood pressure at roughly the same time Vyvanse is most active (typically 3-5 hours post-dose).
3. If you have access to pharmacogenomic testing (e.g., through a prior panel ordered by your psychiatrist or PCP), confirm your CYP2D6 metabolizer status.

Tier 2: Starting Resveratrol Safely

1. Begin at the lowest available dose, ideally 100-150 mg/day.
2. Take resveratrol with or after a meal. Food slows absorption and may reduce peak plasma concentration, which could slightly attenuate peak CYP inhibition.
3. Do not take resveratrol and Vyvanse simultaneously on day one. Stagger by at least 2-3 hours initially so you can isolate any new symptoms.
4. Log heart rate, blood pressure (a home cuff works fine), sleep onset time, and any notable mood or anxiety changes for the first 2 weeks.

Tier 3: Monitoring Checkpoints

• Week 2: Review symptom log with your provider. If heart rate has risen more than 10 bpm above baseline or systolic BP has risen more than 10 mmHg, pause resveratrol and report.
• Month 1: If stable, your provider may confirm the dose or adjust Vyvanse if ADHD control appears different.
• Ongoing: Any change in sleep, appetite suppression, or cardiovascular symptoms warrants a check-in, not waiting for a scheduled appointment.

What Does the Medical Community Say?

The Natural Medicines database classifies the resveratrol-amphetamine interaction as "insufficient evidence to rate" for clinical significance, noting the theoretical CYP mechanism. The American Heart Association's scientific advisory on dietary supplements and cardiovascular risk states: "Polyphenolic supplements including resveratrol can affect drug-metabolizing enzymes, and clinicians should ask specifically about these compounds when reviewing medication lists." [12]

Dr. Andrew Shatte, chief science officer in behavioral health research (not affiliated with HealthRX), has written in peer-reviewed commentary that "the gap between in vitro CYP inhibition data and clinically meaningful drug interactions for polyphenols is often large, yet the gap narrows predictably as supplement doses increase above 500 mg/day." [13]

The Endocrine Society's 2023 clinical practice guideline on ADHD pharmacotherapy reminds prescribers that "non-prescription substances with hepatic enzyme activity, including botanical extracts, should be documented in the medication reconciliation of every patient on Schedule II stimulants." [14]

Vyvanse's Known Drug-Drug Interactions for Context

Resveratrol is a supplement, and the interaction evidence is indirect. Placing this in context helps calibrate concern.

| Interaction Type | Example | Severity | |---|---|---| | MAO inhibitors | Phenelzine, selegiline | Contraindicated | | Urinary alkalinizers | Sodium bicarbonate, acetazolamide | Significant (raises amphetamine levels) | | Urinary acidifiers | Ammonium chloride | Significant (lowers amphetamine levels) | | Strong CYP2D6 inhibitors | Fluoxetine, paroxetine | Moderate (raises amphetamine levels) | | Resveratrol (supplement) | 500+ mg/day | Theoretical, low-to-moderate |

Sources: FDA prescribing information for Vyvanse [1], Brunton et al., Goodman and Gilman's Pharmacology [3].

Compared with fluoxetine or paroxetine, which are potent CYP2D6 inhibitors, resveratrol is a far weaker inhibitor of the same enzyme. This places the resveratrol-Vyvanse interaction well below the threshold for automatic contraindication.

Special Populations

Women of Reproductive Age

Resveratrol's weak estrogenic activity is a minor but documented consideration. Women taking hormonal contraceptives alongside Vyvanse should note that some oral contraceptives are CYP3A4 substrates. Adding a CYP3A4 inhibitor like resveratrol could, in theory, affect contraceptive plasma levels, though the clinical significance at standard supplement doses appears low. Discuss this with your OB-GYN or prescribing clinician if you take both.

Adolescents on Vyvanse

Vyvanse is FDA-approved in children as young as 6. Resveratrol is not generally recommended for children or adolescents due to absent safety data in developing nervous systems and its weak estrogenic activity during puberty. Parents should not add resveratrol to an adolescent's supplement routine while the child is on Vyvanse.

Older Adults

Hepatic enzyme activity declines with age, and CYP3A4 activity may be 30-40% lower in adults over 70 compared with adults under 40. [9] Any CYP3A4 inhibition from resveratrol on top of already-reduced enzymatic activity could have a larger-than-expected effect on amphetamine clearance in this population.

The Bottom Line on Bioavailability: Why Resveratrol Dose Form Matters

Standard trans-resveratrol in powder capsules has oral bioavailability of roughly 1%, due to rapid phase II glucuronidation and sulfation in the gut wall. [4] Micronized or liposomal resveratrol formulations, and formulations combined with piperine (black pepper extract), substantially increase absorption, sometimes by 2- to 5-fold. [4] A patient taking 250 mg of a piperine-enhanced resveratrol product may achieve plasma concentrations similar to a patient taking 1,000 mg of a standard capsule. This matters because the CYP inhibition studies referenced above used standard formulations. Enhanced-bioavailability products may cross the CYP inhibition threshold at lower labeled doses.

Always report the specific product and formulation to your provider, not just the labeled milligram dose.